# Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster

> **NCT02297503** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 61 (actual)

## Conditions studied

- Facial Aesthetic Treatment

## Interventions

- **DRUG:** Azzalure
- **DEVICE:** Restylane/Emervel filler
- **DEVICE:** Restylane Skinbooster

## Key facts

- **NCT ID:** NCT02297503
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297503, "Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02297503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*